Xerostomia Clinical Trial
Official title:
A Natural Formulation for Patients Diagnosed With Xerostomia
Verified date | March 2015 |
Source | Georgia Regents University |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Institutional Review Board |
Study type | Interventional |
The goal of this proposal is to investigate the effectiveness of a Medical College of Georgia patent pending formulation of natural plant extracts on patients with xerostomia. The major component of this formulation is green tea extract with a defined composition of polyphenols. Epidemiological studies suggest that phytochemicals in green tea possess beneficial effects on autoimmune and inflammatory diseases. Thus far, there is little evidence to indicate any marked and direct immunomodulatory effect of green tea on T or B lymphocytes. However, there is considerable evidence for green tea polyphenols (GTPs), major phytochemicals found in green tea extract, having properties consistent with effects on cells of tissues that would be protective towards local inflammation.
Status | Completed |
Enrollment | 60 |
Est. completion date | June 2013 |
Est. primary completion date | June 2013 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 75 Years |
Eligibility |
Inclusion Criteria: 1. A complaint of dry mouth as assessed by a response of 30mm or greater on a Dry Mouth Visual Analog Scale (VAS) 2. Clinical Diagnosis of primary or secondary Sjogren's syndrome. 3. Over the age of 18. 4. Taking less than three drugs associated with causing xerostomia or salivary gland hypofunction. 5. Willing to use natural novel topical dry mouth products. 6. Prior minor salivary gland biopsy and serology from Sjogren's Syndrome/Xerostomia work-up. 7. Willing to return for all study-associated visits. 8. Able to read, understand, and sign the informed consent. Exclusion Criteria: 1. Have received radiation to the head and neck region. 2. Unable to read and understand the consent form. 3. On greater than three drugs associated with xerostomia or salivary gland hypofunction. 4. Require dento-alveolar surgery or extensive dental treatment during the course of the study. 5. Require hospitalization for any medical problem during the course of the study. 6. Unable to take green tea leaf extract and/or pilocarpus jaborandi leaf extract and/or xylitol because of allergy 7. Uncontrolled medical conditions that require changes in medication during the course of the study. 8. Regularly consume green tea and/or components of pilocarpus jaborandi. 9. Are pregnant |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | GHSU Center for Oral Medicine | Augusta | Georgia |
Lead Sponsor | Collaborator |
---|---|
Georgia Regents University | GlaxoSmithKline |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in Salivary Flow From Baseline | Change in salivary flow in Xerostomic patients using Green tea lozenges | 8 weeks | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05342272 -
Comparison of Gum® HydralTM Moisturizing Gel and Biotene® Oral Gel in Dry Mouth Sensation Reduction
|
Phase 3 | |
Completed |
NCT03302676 -
The Use of Chewing Gum for Xerostomia and Hyposalivation After Radiotherapy for Oral and Oropharyngeal Tumors
|
N/A | |
Completed |
NCT02375451 -
Effect of Childhood Radioiodine Therapy on Salivary Function
|
N/A | |
Completed |
NCT01272570 -
Oral Health and Oral Health-Related Quality of Life in Early Stage Breast Cancer Survivors
|
N/A | |
Completed |
NCT00656513 -
Acupuncture-Like Transcutaneous Electrical Nerve Stimulation (ALTENS) or Pilocarpine in Treating Early Dry Mouth in Patients Undergoing Radiation Therapy for Head and Neck Cancer
|
Phase 2/Phase 3 | |
Completed |
NCT00911768 -
Effect of Korean Red Ginseng (KRG) on Dry Mouth
|
Phase 4 | |
Completed |
NCT00332618 -
Efficacy Study of Oxygenated Glycerol Triesters to Treat Xerostomia
|
Phase 2 | |
Completed |
NCT03494985 -
A Clinical Study to Evaluate the Efficacy of Three Dry Mouth Relief Products Versus Water
|
N/A | |
Completed |
NCT05058430 -
SaliPen Human Factors Study for OTC Labeling
|
N/A | |
Recruiting |
NCT02705937 -
Early Phase Study Comparing the Effectiveness of a Dairy Product With the Reference Treatment Aequasyal® on Dry Mouth Symptoms in Patients Suffering From Xerostomia Caused by Psychotropic Medications.
|
N/A | |
Completed |
NCT05247008 -
Effectiveness of Thyme Honey in Management of Xerostomia in ESRD
|
N/A | |
Recruiting |
NCT03632096 -
Photobiomodulation in Salivary Production of Patients With Xerostomy
|
Phase 2 | |
Not yet recruiting |
NCT04323384 -
The Effect of Biotene® on the Symptoms of Xerostomia and Mastication and Swallowing
|
N/A | |
Not yet recruiting |
NCT03530735 -
Finger-prick Autologous Blood (FAB) for Use in Dry Mouth
|
N/A | |
Active, not recruiting |
NCT03176368 -
Coconut Oil: Managing Radiation-Induced Xerostomia
|
N/A | |
Enrolling by invitation |
NCT06122636 -
Efficacy of a Probiotic and Microbiological Analysis on Oral Complications Induced by Antineoplastic Therapies in Patients With HNC
|
N/A | |
Completed |
NCT03611283 -
Topical Management of Xerostomia With Dry Mouth Products
|
N/A | |
Completed |
NCT02682199 -
Prospective Evaluation of Patient Reported Xerostomia After Whole Brain Radiation
|
||
Withdrawn |
NCT01960101 -
Development of a Milk Product Substitution for Patients Suffering From Xerostomia Caused by Medication
|
N/A | |
Completed |
NCT02317172 -
Efficacy of Novel Edible Gel-based Artificial Saliva in Thai Geriatric Populations With Systemic Diseases
|
N/A |